CLINICAL_TRIALS ClinicalTrials.gov record update

A phase1b/2 Study Evaluating the Efficacy of APR-246, a First-in-class Agent Targeting Mutant p53 in the Treatment of Platinum Resistant Advanced and Metastatic Oesophageal or Gastro-oesophageal Junction Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02999893
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:22.289446+00:00
Published At: 2021-12-13T00:00:00+00:00
Record Updated At: 2021-12-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Oesophageal Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-12-13"
protocolSection.identificationModule.nctId: "NCT02999893"
protocolSection.identificationModule.officialTitle: "A phase1b/2 Study Evaluating the Efficacy of APR-246, a First-in-class Agent Targeting Mutant p53 in the Treatment of Platinum Resistant Advanced and Metastatic Oesophageal or Gastro-oesophageal Junction Cancers"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.